Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03692429
Title alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (alloSHRINK)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celyad Oncology SA
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | BEL


No variant requirements are available.